Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Outlook (2023-2033)

Worldwide revenue from the irritable bowel syndrome treatment market stands at US$ 3.4 Bn in 2022, with the global market estimated to surge ahead at a CAGR value of 8.3% to reach a valuation of US$ 8.3 Bn by the end of 2033.

As assessed by Persistence Market Research, linaclotide within product category are expected to hold a market value of US$ 840.2 Mn by 2023. Overall, irritable bowel syndrome treatment market sales account for approximately 9.2% of revenue share in the global gastrointestinal treatment market, which was valued at around US$ 37.0 Bn in 2022.

Sales Analysis of Irritable Bowel Syndrome Treatment from 2016 to 2022 Vs Market Outlook for 2023 to 2033

The global market for irritable bowel syndrome treatment recorded a historic CAGR of 7.4% in the last 6 years from 2016 to 2022.

Irritable bowel syndrome (IBS) is a disorder that mainly affects the gastrointestinal tract, including the stomach and small intestine. Some of the symptoms of IBS include pain in the abdomen, bloating, cramps, acidity, diarrhoea, and constipation. It is a chronic condition that is needed to be managed in long term.

Irritable bowel syndrome is significantly impacted by irregular eating patterns and frequent consumption of fried foods. Foods that are fried, heavily preserved, processed, and made from refined grains contain a lot of fat. This has an impact on the entire digestive system and leads to IBS. Food that has been fried may have undergone chemical changes that make it more difficult to digest and uncomfortable for the digestive system.

The increasing prevalence of gastrointestinal diseases is propelling the market growth. The large intestine is highly affected by irritable bowel syndrome.

• In April 2020, the Journal of Gastroenterology reported that 11% of people worldwide were suffering from GI problems such as irritable bowel syndrome.

Irritable bowel syndrome generally occurs after a severe episode of diarrhoea caused by bacteria or viruses. It might also be linked to an excess or overgrowth of bacteria in the intestines. The intestines are home to various useful bacteria, and other microbes that are essential to sustaining gut health. However, numerous studies have suggested that the microorganisms found in adults with irritable bowel syndrome may be different from those found in healthy individuals.

The global market is thus likely to show high growth over the coming years a CAGR value of 8.3% and reach a global market size of around US$ 8.3 Bn by 2033.

What can Lead to the Growth of Irritable Bowel Syndrome Treatment Market?

“Increased Usage of Drugs for Treatment of Irritable Bowel Syndrome”

The effective management of irritable bowel syndrome has led to an increase in the use of various treatment drug types for irritable bowel syndrome, such as anti-diarrheal medications and alosetron, as measures for treatment other than conventional therapeutic means, and has subsequently led to higher market growth.

It is anticipated that chances for market growth will improve from the increased number of patients and the treatment adoption rate. Additionally, as research and development activities increase, more irritable bowel syndrome treatment drugs will be manufactured that will provide effective results. It is anticipated that this will result in market growth.

There is also an increase in awareness among the common people regarding irritable bowel syndrome. There is growing awareness of the condition as a result of the emergence of severe symptoms including weight loss and discomfort in the stomach in cases where people have disregarded the early IBS symptoms. Weight loss, night time diarrhoea, rectal bleeding, iron deficiency anaemia, unexplained vomiting, and difficulty swallowing are among the severe symptoms of irritable bowel syndrome.

Governments from all over the world are also making significant efforts to improve IBS-related circumstances and raise public awareness. The month of April is recognised as IBS Awareness Month. Throughout this month, numerous public and private groups hold a variety of awareness-raising activities for irritable bowel syndrome.

Can Demand for Irritable Bowel Syndrome Treatment Market Be Affected in Any Way?

“Irritable Bowel Syndrome-Related Social Stigma Has a Negative Impact on the Market”

Talking about the symptoms of irritable bowel syndrome is often uncomfortable. From a social perspective, it is typically frowned upon to talk openly about bowel movement-related concerns. This has caused a lot of IBS people to conceal their condition and live with the crippling pain and ongoing bowel problems in silence. A study found that 57% of irritable bowel syndrome patients experience some kind of stigma related to their illness, with friends, co-workers, and employers being the main perpetrators of this stigma. Thus the above-mentioned factors are a restrain that could have a negative impact on the market.

Also, the irritable bowel syndrome market has a large number of potential participants, which leads to competition in many areas, including pricing and sales. Takeda Pharmaceutical Company Limited, Pfizer, Inc., AstraZeneca PLC, Novartis AG, and many more are prospective major participants in the global irritable bowel syndrome market. As the size of the market and the demand for medications is growing, more firms are beginning to invest in the industry to enhance the market's demand. As a result, the market sees a sharp and quick surge in both sales and competitiveness. The primary reason for competition is the availability of comparable therapeutic options.

Country-wise Insights

Why is the U.S. Irritable Bowel Syndrome Treatment Market Booming?

“Increasing Cases of Irritable Bowel Syndrome Cases in the U.S.”

The U.S. accounted for around 37.5% market share in the global market in 2022, and a similar trend is expected over the forecast period.

The region holds a significant market share because of the increasing cases of IBS due to changes in lifestyle and eating habits, such as the high intake of junk and fatty foods, low levels of physical activity, and the accessibility of therapeutic medications.

Thus, with the above-mentioned factors, there will be continuous growth in the U.S. market in the forecast period as well.

Will U.K. Be a Lucrative Market for Irritable Bowel Syndrome Treatment Market?

“Increasing Per Capita Healthcare Spending in the Country”

The U.K. held around 18.0% market share of the European market in 2022.

The amount spent on healthcare per person is rising globally. Healthcare spending has significantly changed as a result of people's willingness and ability to spend on well-being. The National Health Service (NHS) asserts that the efficient utilization of resources is vital due an underlying financial pressure. At least 12% of people in the United Kingdom are affected by Irritable bowel syndrome.

Thus there is a higher potential for increased usage of irritable bowel syndrome drugs in the upcoming years as well.

How is China Emerging as a Prominent Market for Irritable Bowel Syndrome Treatment?

“Increase Expansion by Global Manufacturers in the Country”

China held a market share of about 63.1% of the East Asia market in 2022.

Irritable bowel syndrome therapy products are now more widely available in China as manufacturers concentrate on growing their global footprint, specialized expertise, and cutting-edge technological capabilities.

For instance, in January 2019, AstraZeneca reported that its partner Ironwood Pharmaceuticals, Inc. had received marketing approval from China's National Medical Products Administration (NMPA) for Linzess (linaclotide), which is used to treat adult patients with constipation-related irritable bowel syndrome.

Thus China is a growing market and is expected to show potential growth in the forecast period.

Category-wise Insights

Which Irritable Bowel Syndrome Treatment Product is Driving Market Growth?

“High Demand for Linaclotide drug across Regions”

The Linaclotide drug segment held the largest market share and are expected to hold a market value of US$ 840.2 Mn by 2023.

Due to Linaclotide's effectiveness in the management of chronic constipation and irritable bowel syndrome with constipation (IBS-C), which was previously unmet by traditional approaches, this medication class is in high demand.

It is because of its higher adoption rate that the demand is expected to consequently improve in the forecast period. The effectiveness of the drug compared to other similar drugs in the market is driving the overall growth.

Why is Irritable Bowel Syndrome with Constipation a Concerning Factor?

“Irritable Bowel Syndrome with Constipation leads to Hemorrhoids”

Irritable Bowel Syndrome with constipation held the largest market share for the indication segment at around 47.9% in 2022.

The patient number for irritable bowel syndrome with constipation is more compared to other irritable bowel syndrome indications such as irritable bowel syndrome with diarrhea and irritable bowel syndrome with alternating constipation and diarrhea. Irritable bowel syndrome with constipation also leads to hemorrhoids and thus deteriorates the quality of life of the individual. The day-to-day activities of individuals are highly affected because of this condition.

Which Distribution Channel is Most Preferred for Irritable Bowel Syndrome Treatment Drug Sales?

“Growing Sales of Drugs in Retail Pharmacies”

Retail pharmacies hold a larger share of about 30.5% in 2022 globally.

The rising awareness of the treatment options for irritable bowel syndrome and their accessibility are driving the market for retail pharmacies. The sales rate in retail pharmacies is comparatively higher than other distribution channels such as hospital pharmacies, drug stores, online pharmacies or hypermarkets, and supermarkets.

Thus taking these factors into consideration, it is observed that retail pharmacies hold the highest market share as distribution channel in the market.

Competitive Landscape

To improve their product lines across the globe, the leading manufacturers are developing technologically advanced products. The major competitors in the irritable bowel syndrome treatment industry are involved in several consolidation activities such as product launches and mergers and acquisitions.

For instance:

• In March 2021, Abbott and Nutrition Society of India partenered together in order to raise awareness amongst patients suffering from GI conditions by introducing India-specific clinical dietary recommendations. GI conditions range from functional constipation to peptic ulcers, chronic pancreatitis, and irritable bowel syndrome.
• In March 2021, Bausch Health Companies Inc. launched GastroHub for advanced practice providers. It is an educational website designed with information related to treatment of IBS-D as well as HE for nurse practitioners and physician assistants.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the irritable bowel syndrome treatment market, which are available in the full report.

Irritable Bowel Syndrome Treatment Industry Report Scope

Key Segments Covered in Irritable Bowel Syndrome Treatment Industry Research

By Product:

• Fiber Supplements
• Anti-Diarrheal
• Anticholinergic and Antispasmodic
• Antidepressant
• Antibiotics
• Alosetron
• Lubiprostone
• Linaclotide
• NHE3

By Indication:

• Irritable Bowel Syndrome with Constipation
• Irritable Bowel Syndrome with Diarrhoea
• Irritable Bowel Syndrome with alternating Constipation and Diarrhoea

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies and Stores
• Hypermarkets and Supermarkets

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales